Unveiling the Potential of AFM24 in EGFR-Wildtype Non-Small Cell Lung Cancer: Insights from the AFM24-102 Phase 1/2a Study

Scheduled for:Feb 28, 2024 7:00 PM EDT

Call Duration:30 minutes

Desired Expert

An oncologist or lung cancer specialist with expertise in NSCLC and experience in clinical trials. The expert should have a deep understanding of NSCLC treatment, especially in the context of EGFR-wildtype cases, and be familiar with the latest advancements in immunotherapy and targeted treatments.

Interview Goal

This interview aims to explore the significant findings from the AFM24-102 Phase 1/2a trial of AFM24 in patients with EGFR-wildtype non-small cell lung cancer (NSCLC). We will discuss the drug's efficacy, safety, and its potential impact on the treatment landscape for NSCLC, particularly in patients who have progressed on PD-[L]1 targeted therapy.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.